Cohort study reveals frequent high PD-L1 expression in ROS1-rearranged non-small cell lung cancer, suggesting potential relevance for immune checkpoint therapies.
In the largest consecutive routine Asian NSCLC cohort analyzed to date, we found that high PD-L1 expression frequently overlapped with ROS1 rearrangement, while it negatively correlated with EGFR mutations.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: